3 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
TESARO, Inc. (TSRO) boosts its rating from a B to a A this week. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TSRO stock.
Abeona Therapeutics, Inc.’s (ABEO) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of ABEO stock.
Nymox Pharmaceutical Corp (NYMX) shows solid improvement this week. The company’s rating rises from a C to a B. Nymox Pharmaceutical Corp is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NYMX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.